Literature DB >> 15598815

Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States.

Fausto R Loberiza1, Mei-Jie Zhang, Stephanie J Lee, John P Klein, Charles F LeMaistre, Derek S Serna, Mary Eapen, Christopher N Bredeson, Mary M Horowitz, J Douglas Rizzo.   

Abstract

The effect of the organization and delivery of health care at medical centers, referred to as "center effects," with clinical outcomes after hematopoietic stem cell transplantation (HSCT) is not clear. We examined the association between center and treatment provider factors and mortality after HSCT. We surveyed 163 (87% response rate) United States transplantation centers that performed HLA-identical sibling HSCT for leukemia or autologous HSCT for lymphoma between 1998 and 2000 among patients at least 18 years old. One hundred thirteen (69%) centers performed HLA-identical sibling transplantations, whereas 162 (99%) performed autologous transplantations. Factors associated with decreased 100-day mortality in the allogeneic setting include a higher patient-per-physician ratio (P = .003) and centers where physicians answer calls after office hours (P = .03). Medical school affiliation was not associated with increased 100-day mortality except in centers where students/residents are present without fellows (P = .02). Center effects were weaker in autologous HSCT at 1 year. Differences in 100-day mortality in patients receiving transplants in centers with favorable versus unfavorable factors were greater in allogeneic than autologous HSCT. Greater physician involvement in patient care is important in producing favorable outcomes after HSCT. To more clearly establish the role of the factors we identified, further studies are recommended.

Entities:  

Mesh:

Year:  2004        PMID: 15598815     DOI: 10.1182/blood-2004-10-3863

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT.

Authors:  Sebastian Giebel; Myriam Labopin; Adalberto Ibatici; Paul Browne; Tomasz Czerw; Gerard Socie; Ali Unal; Slawomira Kyrcz-Krzemien; Andrea Bacigalupo; Hakan Goker; Mike Potter; Caroline L Furness; Grant McQuaker; Dietrich Beelen; Noel Milpied; Antonio Campos; Charles Craddock; Arnon Nagler; Mohamad Mohty
Journal:  Oncologist       Date:  2016-02-11

2.  Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.

Authors:  Scott F Huntington; Jessica R Hoag; Weiwei Zhu; Rong Wang; Amer M Zeidan; Smith Giri; Nikolai A Podoltsev; Steven D Gore; Xiaomei Ma; Cary P Gross; Amy J Davidoff
Journal:  Cancer       Date:  2018-09-14       Impact factor: 6.860

3.  Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.

Authors:  Karen K Ballen; Steven Joffe; Ruta Brazauskas; Zhiwei Wang; Mahmoud D Aljurf; Görgün Akpek; Christopher Dandoy; Haydar A Frangoul; César O Freytes; Nandita Khera; Hillard M Lazarus; Charles F LeMaistre; Paulette Mehta; Susan K Parsons; David Szwajcer; Celalettin Ustun; William A Wood; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-23       Impact factor: 5.742

4.  Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia.

Authors:  Benny Lee; Ozge Goktepe; Kevin Hay; Joseph M Connors; Laurie H Sehn; Kerry J Savage; Tamara Shenkier; Richard Klasa; Alina Gerrie; Diego Villa
Journal:  Oncologist       Date:  2014-02-25

Review 5.  Optimizing Quality and Efficiency of Healthcare Delivery in Hematopoietic Cell Transplantation.

Authors:  Navneet S Majhail
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

Review 6.  Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Authors:  J Khosla; A C Yeh; T R Spitzer; B R Dey
Journal:  Bone Marrow Transplant       Date:  2017-10-02       Impact factor: 5.483

7.  Bone marrow transplant for multiple myeloma: impact of distance from the transplant center.

Authors:  Brea C Lipe; Frederick Lansigan; Jiang Gui; Kenneth Meehan
Journal:  Clin Adv Hematol Oncol       Date:  2012-01

8.  Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience.

Authors:  Igne Kairiene; Ramune Pasauliene; Nadezda Lipunova; Goda Vaitkeviciene; Lina Rageliene; Jelena Rascon
Journal:  Eur J Pediatr       Date:  2017-08-15       Impact factor: 3.183

9.  Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.

Authors:  Jie Ji; Benigno C Valdez; Yang Li; Yan Liu; Esmeralda C Teo; Yago Nieto; Richard E Champlin; Borje S Andersson
Journal:  Exp Hematol       Date:  2016-03-11       Impact factor: 3.084

10.  The effect of specialized cancer treatment centers on treatment efficacy in Hodgkin's lymphoma.

Authors:  Beate Klimm; Corinne Brillant; Nicole Skoetz; Horst Müller; Andreas Engert; Peter Borchmann
Journal:  Dtsch Arztebl Int       Date:  2012-12-24       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.